Eledon Pharmaceuticals (ELDN) Invested Capital (2016 - 2017)
Historic Invested Capital for Eledon Pharmaceuticals (ELDN) over the last 5 years, with Q3 2017 value amounting to $20.6 million.
- Eledon Pharmaceuticals' Invested Capital fell 3185.38% to $20.6 million in Q3 2017 from the same period last year, while for Sep 2017 it was $20.6 million, marking a year-over-year decrease of 3185.38%. This contributed to the annual value of -$2.7 million for FY2016, which is 10437.76% down from last year.
- As of Q3 2017, Eledon Pharmaceuticals' Invested Capital stood at $20.6 million, which was down 3185.38% from $23.4 million recorded in Q2 2017.
- In the past 5 years, Eledon Pharmaceuticals' Invested Capital ranged from a high of $103.5 million in Q4 2014 and a low of -$55.3 million during Q4 2013
- Moreover, its 5-year median value for Invested Capital was $45.1 million (2016), whereas its average is $45.9 million.
- Its Invested Capital has fluctuated over the past 5 years, first soared by 28727.45% in 2014, then plummeted by 10437.76% in 2016.
- Quarter analysis of 5 years shows Eledon Pharmaceuticals' Invested Capital stood at -$55.3 million in 2013, then skyrocketed by 287.27% to $103.5 million in 2014, then tumbled by 40.36% to $61.7 million in 2015, then crashed by 104.38% to -$2.7 million in 2016, then surged by 863.1% to $20.6 million in 2017.
- Its last three reported values are $20.6 million in Q3 2017, $23.4 million for Q2 2017, and $23.4 million during Q1 2017.